A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023
China CDC Weekly · 2026 · 8 (17) · 513-519
DOI: 10.46234/ccdcw2026.083 ↗Kurz gefasst
Fachartikel in der Zeitschrift China CDC Weekly, 2026. Verfasst von Jingyu Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan Province, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan Province, China.
- State Key Laboratory of Antibody Research and Development, North China Pharmaceutical Company (NCPC) New Drug Research and Development Co., Ltd., Shijiazhuang City, Hebei Province, China.
- Mile Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
- Gejiu Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
- Kaiyuan Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
- Qiubei County Center for Disease Control and Prevention, Wenshan Zhuang and Miao Autonomous Prefecture, Yunnan Province, China.
Zitieren
APA
Li, J., Zhao, Y., Zheng, Y., Zhang, X., Jiang, Y., Guo, J., Bao, W., Ma, Y., Zhang, Y., Yin, S., Ma, Y., Wang, L., & Liu, X. (2026). A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023. China CDC Weekly, 8(17), 513-519. https://doi.org/10.46234/ccdcw2026.083
Vancouver
Li J, Zhao Y, Zheng Y, Zhang X, Jiang Y, Guo J, et al. A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023. China CDC Weekly. 2026;8(17):513-519. doi:10.46234/ccdcw2026.083
BibTeX
@article{Li2026,
author = {Li, Jingyu and Zhao, Yu and Zheng, Yan and Zhang, Xuexia and Jiang, Ya and Guo, Jiangshu and Bao, Wenmei and Ma, Yinfeng and Zhang, Yaoyuan and Yin, Shuyuan and Ma, Yirui and Wang, Lijie and Liu, Xiaoqiang},
title = {A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023},
journal = {China CDC Weekly},
year = {2026},
volume = {8},
number = {17},
pages = {513--519},
doi = {10.46234/ccdcw2026.083}
}
EUVIMED